View Filing Data

Print Document View Excel Document

Document And Entity Information	3 Months Ended
Document And Entity Information	Mar. 31, 2016 shares
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q1
Entity Registrant Name	FLAMEL TECHNOLOGIES SA
Entity Central Index Key	0001012477
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Trading Symbol	FLML
Entity Common Stock, Shares Outstanding	41,241,254

Consolidated Statements of Income (Loss) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues:
Product sales and services	$ 35,353	$ 32,726
License and research revenue	863	0
Total	36,216	32,726
Operating expenses:
Cost of products and services sold	4,395	3,630
Research and development expenses	5,388	6,022
Selling, general and administrative expenses	9,461	4,463
Intangible asset amortization	3,514	3,143
Changes in fair value of related party acquisition-related contingent consideration	7,916	5,254
Total	30,674	22,512
Operating income	5,542	10,214
Investment Income	200	664
Interest Expense	(175)	0
Interest Expense - changes in fair value of related party financing-relatedcontingent consideration	(1,861)	(259)
Foreign exchange gain (loss)	(2,941)	11,501
Income before income taxes	765	22,120
Income tax provision	7,141	10,473
Net income (loss)	$ (6,376)	$ 11,647
Earnings (loss) per share - Basic:
Net income (loss) per share - Basic (in dollars per share)	$ (0.15)	$ 0.29
Earnings (loss) per share - Diluted:
Net income (loss) per share - Diluted (in dollars per share)	$ (0.15)	$ 0.27
Earnings (loss) per share
Weighted average number of shares outstanding - Basic (in shares)	41,241	40,207
Weighted average number of shares outstanding - Diluted (in shares)	41,241	42,879

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net income/(loss)	$ (6,376)	$ 11,647
Other comprehensive income/(loss), net of tax:
Foreign currency translation gain/(loss), net	4,817	(16,649)
Unrealized gains on marketable securities	918	356
Total other comprehensive income/(loss), net of tax	5,735	(16,293)
Total comprehensive loss	$ (641)	$ (4,646)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 37,870	$ 65,064
Marketable securities	122,084	79,738
Accounts receivable (net of allowance of $35 at both March 31, 2016 and December 31, 2015)	4,865	6,978
Inventories	5,312	4,155
Research and development tax credit receivable - current portion	368	2,382
Prepaid expenses and other current assets	9,975	7,989
Total current assets	180,474	166,306
Property and equipment, net	3,100	2,616
Goodwill	24,055	18,491
Intangible assets, net	32,911	15,825
Research and development tax credit receivable - less current portion	2,490	0
Income tax deferred charge	11,964	11,581
Other	16	158
Total assets	255,010	214,977
Current liabilities:
Current portion of long-term debt	454	434
Current portion of long-term related party contingent consideration payable	28,403	28,614
Accounts payable	17,674	10,565
Deferred revenue	4,611	5,121
Accrued expenses	3,346	3,598
Income taxes	5,844	323
Other	611	133
Total current liabilities	60,943	48,788
Long-term debt, less current portion	710	684
Long-term related party contingent consideration payable, less current portion	102,656	94,079
Long-term related party payable	15,000	0
Deferred taxes	3,507	1,351
Other	2,495	2,210
Total liabilities	185,311	147,112
Shareholders' equity:
Ordinary shares, nominal value of 0.122 euro per share; 53,178 shares authorized; 41,241 issued and outstanding at March 31, 2016 and December 31, 2015, respectively	6,331	6,331
Additional paid-in capital	366,459	363,984
Accumulated deficit	(286,169)	(279,793)
Accumulated other comprehensive loss	(16,922)	(22,657)
Total shareholders' equity	69,699	67,865
Total liabilities and shareholders' equity	$ 255,010	$ 214,977

Consolidated Balance Sheets [Parenthetical] $ in Thousands	Mar. 31, 2016 USD ($) shares	Mar. 31, 2016 € / shares	Dec. 31, 2015 USD ($) shares	Dec. 31, 2015 € / shares
Allowance for accounts receivable (in dollars) \| $	$ 35		$ 35
Common stock, par value (in euro per share) \| € / shares		€ 0.122		€ 0.122
Common stock, shares authorized	53,178		53,178
Common stock, shares issued	41,241		41,241
Common stock, shares outstanding	41,241		41,241

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net income (loss)	$ (6,376)	$ 11,647
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	3,754	3,260
Loss on disposal of property and equipment	102	0
Loss (gain) on sale of marketable securities	285	(489)
Unrealized exchange loss (gain)	2,941	(11,296)
Remeasurement of related party acquisition-related contingent consideration	7,916	5,254
Remeasurement of related party financing-related contingent consideration	1,861	259
Change in deferred tax and income tax deferred charge	(1,682)	5,864
Stock-based compensation expense	2,475	1,593
Increase (decrease) in cash from:
Accounts receivable	2,120	1,376
Inventories	1,212	1,207
Prepaid expenses and other current assets	(206)	(368)
Research and development tax credit receivable	(363)	(127)
Accounts payable & other current liabilities	4,029	2,295
Deferred revenue	(758)	2,177
Accrued expenses	(809)	(858)
Accrued income taxes	5,520	3,283
Other long-term assets and liabilities	477	198
Net cash provided by operating activities	22,498	25,275
Cash flows from investing activities:
Purchases of property and equipment	(460)	(234)
Acquisitions of businesses	161	0
Proceeds from sales of marketable securities	9,766	2,817
Purchase of marketable securities	(50,454)	(26,012)
Net cash used in investing activities	(40,987)	(23,429)
Cash flows from financing activities:
Earn-out payments for related party acquisition-related contingent consideration	(8,014)	(325)
Royalty payments for related party financing-related contingent consideration	(1,092)	0
Cash proceeds from issuance of ordinary shares and warrants	0	246
Net cash used in financing activities	(9,106)	(79)
Effect of exchange rate changes on cash and cash equivalents	401	(2,992)
Net decrease in cash and cash equivalents	(27,194)	(1,225)
Cash and cash equivalents at January 1	65,064	39,760
Cash and cash equivalents at March 31	$ 37,870	$ 38,535

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

NOTE 1 : Summary of Significant Accounting Policies

Nature of Operations. Flamel Technologies S.A. (“Flamel,” the “Company,” “we” or “us”) is organized as a Société Anonyme, a form of corporation under the laws of The Republic of France. The Company was founded in 1990. Flamel is a specialty pharmaceutical company utilizing core competencies in drug delivery and formulation development to create safer and more efficacious pharmaceutical products to address unmet medical needs and/or reduce overall healthcare costs. The Company has a balanced business model consisting of:

(i)

an Unapproved Marketed Drugs (“UMDs”) business with two approved products in the USA, Bloxiverz^® (neostigmine methylsulfate injection) and Vazculep^® (phenylephrine hydrochloride injection) that are currently marketed, a third product, Akovaz® (ephedrine sulphate injection) for which we obtained FDA approval on April 29, 2016 and which we intend to begin marketing in the third quarter of 2016, and a fourth product currently being studied by us for possible submission for review by the FDA, all obtained through the acquisition of Éclat Pharmaceuticals, LLC’s (or “Éclat”) portfolio on March 13, 2012,

(ii)

a branded pediatric specialty pharmaceutical business, acquired through the acquisition of FSC Laboratories and FSC Pediatrics (“FSC”) on February 5, 2016; and

(iii)

a branded business, focusing on the development of products utilizing Flamel’s proprietary drug delivery platforms. The branded products that are based on Flamel’s proprietary drug delivery platforms target high-value solid oral and alternative dosage forms using 505(b)(2) and Biosimilar pathways where the Company can develop strong intellectual property positions and deliver meaningful patient benefits.

Flamel is headquartered in Lyon, France and has operations in St. Louis, Missouri and Charlotte, NC, USA, and Dublin, Ireland.

Basis of Presentation. The consolidated balance sheet as of December 31, 2015, which is derived from the prior year 2015 audited consolidated financial statements, and the interim unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP), the requirements of Form 10-Q and Article 10 of Regulation S-X and, consequently, do not include all information or footnotes required by U.S. GAAP for complete financial statements or all the disclosures normally made in an annual report on Form 10-K. Accordingly, the unaudited consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s 2015 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 15, 2016.

The unaudited consolidated financial statements include the accounts of the Company and all majority-owned subsidiaries, and reflect all adjustments (consisting only of normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the dates and periods presented. All significant intercompany accounts and transactions have been eliminated. Results for interim periods are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period.

Foreign Currency Translation. The reporting currency of the Company and its wholly-owned subsidiaries is the U.S. dollar. Each of the Company's non-U.S. subsidiaries and the parent entity uses local currency as its functional currency. Subsidiaries and entities that do not use the U.S. Dollar as their functional currency translate 1) profit and loss accounts at the weighted average exchange rates during the reporting period, 2) assets and liabilities at period end exchange rates and 3) shareholders' equity accounts at historical rates. Resulting translation gains and losses are included as a separate component of stockholders' equity in Accumulated Other Comprehensive Income. Assets and liabilities denominated in a currency other than the subsidiary's functional currency are translated to the subsidiary's functional currency at period end exchange rates. Resulting gains and losses are recognized in the consolidated statements of income.

Reclassifications. The accompanying consolidated financial statements for prior years contain certain reclassifications to conform to the presentation used in 2016.

Revenue. Revenue includes sales of pharmaceutical products, upfront licensing fees, milestone payments for R&D achievements, and compensation for the execution of R&D activities.

Product Sales and Services

Revenue is generally realized or realizable and earned when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the seller’s price to the buyer is fixed or determinable, and collectability is reasonably assured. The Company records revenue from product sales when title and risk of ownership have been transferred to the customer, which is typically upon delivery to the customer and when the selling price is determinable. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of deductions in arriving at reported net product sales. When the Company recognizes revenue from the sale of its products, an estimate of provision for sales return and allowances is recorded which reduces product sales. These adjustments include estimates for product returns, chargebacks, payment discounts and other sales allowances and rebates. The estimate for chargebacks is determined when product is shipped from the wholesalers to their customers. The return allowance, when estimable, is based on an analysis of the historical returns of the product or similar products.

For generic products and branded products sold in mature and stable markets where changes in selling price are rare, the Company recognizes revenues upon shipment. For products where market conditions remain volatile and selling price is subject to changes, the Company delays revenue recognition until the wholesaler sells the product through to its customers. For new product launches the Company recognizes revenue once sufficient data is available to determine product acceptance in the marketplace such that product returns may be estimated based on historical data and there is evidence of reorders and consideration is made of wholesaler inventory levels. Net product sales of wholesalers to their customers are determined using sales data from an independent wholesaler inventory tracking service. Net sales of wholesalers to their customers are calculated by deducting estimates for returns for wholesaler customers, chargebacks, payment discounts and other sales or discounts offered from the applicable gross sales value. Estimates for product returns are adjusted periodically based upon historical rates of returns, inventory levels in the distribution channel and other related factors.

License and Research Revenue

Where agreements have more than one deliverable, a determination is made as to whether the license and R&D elements should be recognized separately or combined into a single unit of account in accordance with ASU 2009-13, Revenue with Multiple Deliverables.

The Company uses a Multiple Attribution Model, referred to as the milestone-based method:

⋅

As milestones relate to discrete development steps (i.e., can be used by the partners to decide whether to continue the development under the agreement), the Company views that milestone events have substance and represent the achievement of defined goals worthy of the payments. Therefore, milestone payments based on performance are recognized when the performance criteria are met and there are no further performance obligations.

⋅

Non-refundable technology access fees received from collaboration agreements that require the Company's continuing involvement in the form of development efforts are recognized as revenue ratably over the development period.

⋅

Revenue associated with signed feasibility study agreements is recognized over the term of the agreement as services are performed.

Newly Issued Accounting Pronouncements

3 Months Ended

Mar. 31, 2016

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

New Accounting Pronouncements and Changes in Accounting Principles [Text Block]

NOTE 2 : Newly Issued Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") 2014-09 “Revenue from Contracts with Customers” which supersedes the most current revenue recognition requirements. This ASU requires entities to recognize revenue in a way that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the entity expects to be entitled to in exchange for those goods or services. In March and April 2016, the FASB issued ASU 2016-08 “Principal versus Agent Considerations (Reporting Revenue Gross versus Net)” related to principal versus agent considerations and ASU 2016-10 “Identifying Performance Obligations and Licensing” related to identifying performance obligations and licensing, which provide supplemental adoption guidance and clarification to ASU 2014-09, respectively. These ASUs will be effective for annual and interim periods beginning after December 15, 2017 with early adoption for annual and interim periods beginning after December 15, 2016 permitted and should be applied retrospectively to each prior reporting period presented or as a cumulative effect adjustment as of the date of adoption. The Company is currently evaluating this pronouncement to determine the impact of its adoption on its consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09 “Improvements to Employee Share-Based Payment Accounting” which amends ASC Topic 718 “Compensation – Stock Compensation”. This update simplifies several aspects of accounting for share-based payment awards to employees, including the accounting for income taxes, classification of awards as either equity or liabilities and classification in the statement of cash flows. The standard is effective for annual reporting periods beginning after December 15, 2016. The Company is currently evaluating the effect of this update on its consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02 “Leases” which supersedes ASC 840 “Leases” and creates a new topic, ASC 842 "Leases." This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months. The update also expands the required quantitative and qualitative disclosures surrounding leases. This update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years, with earlier application permitted. This update will be applied using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the effect of this update on its consolidated financial statements.

In November 2015, the FASB issued ASU 2015-17 “Balance Sheet Classification of Deferred Taxes” which requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. ASU 2015-17 is effective for the Company in its first quarter of fiscal 2017, with early application permitted and, upon adoption, may be applied either prospectively or retrospectively. The Company early adopted the provisions of ASU 2015-17 for the year ended December 31, 2015 on a prospective basis.

In July 2015, the FASB issued ASU 2015-11 “Simplifying the Measurement of Inventory”, which requires an entity to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The effective date for the standard is for fiscal years beginning after December 15, 2016, which for the Company is January 1, 2017. Early adoption is permitted. The new standard is to be applied prospectively. The Company does not expect ASU 2015-11 to have a material impact on its consolidated financial statements.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6510796

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e725-108305

+ Details

Marketable Securities

3 Months Ended

Mar. 31, 2016

Investments, Debt and Equity Securities [Abstract]

Cash Cash Equivalents And Marketable Securities [Text Block]

NOTE 3 : Marketable Securities

The Company has investments in available-for-sale marketable equity securities which are recorded at fair market value and measured using quoted prices in their respective active market, thus representing a level 1 fair value measurement as defined in ASC 820. Unrealized gains and losses are recorded as other comprehensive income (loss) in shareholders’ equity, net of income tax effects.

The value at cost, gross unrealized holding gains or losses, and fair value of the Company’s available-for-sale marketable securities are summarized below as of:

	March 31,		December 31,
	2016		2015
Value at cost	$	122,823	$	81,395
Gross unrealized holding gains		614		15
Gross unrealized holding losses		(1,353)		(1,672)
Fair value	$	122,084	$	79,738

Inventories

3 Months Ended

Mar. 31, 2016

Inventory Disclosure [Abstract]

Inventory Disclosure [Text Block]

NOTE 4 : Inventories

The principal categories of inventories at December 31, 2015 and 2014 are as follows:

	March 31,		December 31,
	2016		2015
Finished Goods	$	5,046	$	2,545
Raw Materials		266		1,610
Total	$	5,312	$	4,155

Acquisitions

3 Months Ended

Mar. 31, 2016

Business Combinations [Abstract]

Business Combination Disclosure [Text Block]

NOTE 5 : Acquisitions

On February 5, 2016, the Company completed its acquisition of FSC Holdings, LLC (“FSC”), a Charlotte, NC-based specialty pharmaceutical company dedicated to providing innovative solutions to unmet medical needs for pediatric patients, from Deerfield CSF, LLC, a Deerfield Management company (“Deerfield”), a related party.

This acquisition has been accounted for using the acquisition method of accounting and, accordingly, its results are included in the Company's consolidated financial statements from the date of acquisition. Total consideration to acquire FSC was $22,695 and was funded with a combination of the following:

$15,000 long-term liability to Deerfield. Under the terms of the acquisition agreement, the Company will pay $1,050 annually for five years with a final payment in January 2021 of $15,000. The present value of these discounted future cash flows is reported in Long-term related party payable within the Company’s Consolidated Balance Sheets.

$7,695 contingent consideration to Deerfield. Under the terms of the acquisition agreement, the Company shall pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years. The present value of these estimated discounted future cash flows is reported in Long-term contingent consideration payable within the Company’s Consolidated Balance Sheets, and is further disclosed at Note 7 – Long-term Contingent Consideration Payable.

During the first quarter of 2016, the Company determined its preliminary accounting for the FSC acquisition. As the Company completes its final accounting for the acquisition, future adjustments related to working capital, amortizable intangible assets, goodwill and deferred taxes could occur. The preliminary fair values assigned to the acquired assets and liabilities have been recognized as follows:

Assigned Fair Value:
Inventories	$	2,360
Prepaid expenses and other current assets		1,711
Goodwill		5,564
Intangible assets:
Acquired product marketing rights		16,200
Acquired developed technology		4,400
Other assets		278
Accounts payable and other current liabilities		(3,868)
Deferred tax liabilities		(3,950)
Total	$	22,695

Goodwill resulting from the acquisition is largely attributable to the existing workforce of FSC, and is not expected to be deductible for tax purposes. Transaction expenses for legal and professional fees associated with the acquisition of FSC amounted to $76 during the first quarter of 2016 and are reported within the Selling, general and administrative expenses line in the consolidated statements of income.

FSC contributed $876 and ($1,393) to the Company's first quarter 2016 net revenues and net loss, respectively, after its acquisition on February 5, 2016. Had the FSC acquisition been completed as of the beginning of 2015, the Company's unaudited pro forma net sales for the three months ended March 31, 2016 and 2015 would have been $36,694 and $33,226, respectively, and the Company's unaudited pro forma net income (loss) for the same periods would have been ($7,390) and $8,480, respectively.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Goodwill and Intangible Assets

3 Months Ended

Mar. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure [Text Block]

NOTE 6 : Goodwill and Intangible Assets

The Company's amortizable and unamortizable intangible assets at March 31, 2016 and December 31, 2015 are as follows:

	March 31, 2016						December 31, 2015
	Gross Value		Accumulated Amortization		Net Carrying Amount		Gross Value		Accumulated Amortization		Net Carrying Amount
Amortizable intangible assets:
Acquired IPR&D - Bloxiverz	$	35,248	$	(26,435)	$	8,813	$	35,248	$	(23,498)	$	11,750
Acquired IPR&D - Vazculep		12,061		(8,190)		3,871		12,061		(7,986)		4,075
Acquired product marketing rights		16,200		(300)		15,900		-		-		-
Acquired developed technology		4,400		(73)		4,327		-		-		-
Total amortizable intangible assets	$	67,909	$	(34,998)	$	32,911	$	47,309	$	(31,484)	$	15,825

Unamortizable intangible assets:
Goodwill		24,599		(544)		24,055		19,035		(544)		18,491
Total unamortizable intangible assets	$	24,599	$	(544)	$	24,055	$	19,035	$	(544)	$	18,491

The Company recorded amortization expense related to amortizable intangible assets of $3,514 and $3,143 for the three months ended March 31, 2016 and 2015, respectively.

Amortizable intangible assets are amortized over their estimated useful lives, which range from three to ten years. Estimated amortization of intangible assets for the next five years is as follows:

Years ending December 31,	Estimated Amortization Expense
2016	$	14,616
2017		3,056
2018		3,056
2019		3,056
2020		3,056
Total	$	26,840

The change in net goodwill during the three months ended March 31, 2016 is as follows:

Balance - December 31, 2015	$	18,491
Impact of FSC Acquisition		5,564
Balance - March 31, 2016	$	24,055

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Long-Term Contingent Consideration Payable

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Long Term Contingent Consideraion Payable [Text Block]

NOTE 7 : Long-Term Contingent Consideration Payable

Long-term contingent consideration payable and related activity are reported at fair value and consist of the following at March 31, 2016 and December 31, 2015:

			Activity During Quarter Ended March 31, 2016
							Changes in Fair Value of Contingent Consideration
	Balance,						Operating Expense;		Interest Expense;		Balance,
	December 31, 2015		Additions		Payments to Related Parties		Acquisition- Related		Financing- Related		March 31, 2016

Acquisition-related:
Warrants - Éclat Pharmaceuticals (a)	$	20,617	$	-	$	-	$	(3,535)	$	-	$	17,082
Earn-out payments - Éclat Pharmaceuticals (b)		90,468		-		(8,014)		11,451		-		93,905
Financing-related:
Royalty agreement - Deerfield (c)		7,862		-		(739)		-		1,038		8,161
Royalty agreement - Broadfin (d)		3,746		-		(353)		-		496		3,889
Royalty agreement - FSC (e)		-		7,695		-		-		327		8,022
Total contingent consideration	$	122,693	$	7,695	$	(9,106)	$	7,916	$	1,861	$	131,059
Less: Current portion		(28,614)										(28,403)
Total long-term contingent consideration payable	$	94,079									$	102,656

(a)

As part of the consideration for the Company’s acquisition of Éclat Pharmaceuticals, LLC on March 13, 2012, the Company issued two warrants with a six-year term which allow for the purchase of a combined total of 3,300 ordinary shares of Flamel. One warrant is exercisable for 2,200 shares at an exercise price of $7.44 per share, and the other warrant is exercisable for 1,100 shares at an exercise price of $11.00 per share.

The fair value of the warrants is estimated on a quarterly basis using a Black-Scholes option pricing model with the following assumptions as of March 31,:

	2016			2015
Weighted average exercise price per share	$	8.63		$	8.63
Expected term (years)		2.00			3.00
Expected volatility		70.50	%		61.80	%
Risk-free interest rate		0.73	%		0.89	%
Expected dividend yield		-			-

These Black-Scholes fair value measurements are based on significant inputs not observable in the market and thus represent a level 3 measurement as defined in ASC 820. The fair value of the warrant consideration is most sensitive to movement in the Company’s share price and expected volatility at the balance sheet date.

Expected term: The expected term of the options or warrants represents the period of time between the grant date and the time the options or warrants are either exercised or forfeited, including an estimate of future forfeitures for outstanding options or warrants. Given the limited historical data and the grant of stock options and warrants to a limited population, the simplified method has been used to calculate the expected life.

Expected volatility: The expected volatility is calculated based on an average of the historical volatility of the Company's stock price for a period approximating the expected term.

Risk-free interest rate: The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant and a maturity that approximates the expected term.

Expected dividend yield: The Company has not distributed any dividends since its inception, and has no plan to distribute dividends in the foreseeable future.

At the closing date of the 2012 Éclat acquisition and at March 31, 2016, it was uncertain as to whether the Company would ultimately fulfill its obligation under these warrants using Company shares or cash. Accordingly, pursuant to the guidance of ASC 480, the Company determined that these warrants should be classified as a long-term liability. This classification as a long-term liability was further supported by the Company’s determination, pursuant to the guidance of ASC 815-40-15-7(i), that these warrants could also not be considered as being indexed to the Company’s own stock, on the basis that the exercise price for the warrants is determined in U.S. dollars, although the functional currency of the Company at the closing date of the Éclat acquisition was the Euro.

(b)

As part of the consideration for the Company’s acquisition of Éclat Pharmaceuticals, LLC in March 2012, the Company committed to provide quarterly earn-out payments equal to 20% of any gross profit generated by certain Éclat Pharmaceuticals products. These payments will continue in perpetuity, to the extent revenues of the related product also continue in perpetuity.

(c)

As part of a February 2013 debt financing transaction conducted with Deerfield Management, a related party and current shareholder, the Company received cash of $2,600 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 1.75% royalty on the net sales of certain Éclat Pharmaceuticals products until December 31, 2024.

(d)

As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of $2,200 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 0.834% royalty on the net sales of certain Éclat Pharmaceuticals products until December 31, 2024.

(e)

As part of the consideration for the Company’s acquisition of FSC Holdings, LLC in February 2016, the Company entered into a royalty agreement whereby the Company shall pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years.

At March 31, 2016, the fair value of each contingent consideration item in (b) through (e) above was estimated using a discounted cash flow model based on probability-adjusted annual net revenues or gross profit, as appropriate, of each of the specified Éclat Pharmaceuticals and FSC products at an appropriate discount rate. These fair value measurements are based on significant inputs not observable in the market and thus represent a level 3 measurement as defined in ASC 820. Subsequent changes in the fair value of the acquisition-related and financing-related contingent consideration payable, resulting primarily from management’s revision of key assumptions, will be recorded in the changes in fair value of related party acquisition-related contingent consideration and interest expense – changes in fair value of related party financing-related contingent consideration lines, respectively, within the Company’s Consolidated Statements of Income.

Income Taxes

3 Months Ended

Mar. 31, 2016

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

NOTE 8 : Income Taxes

The components of income (loss) before income taxes are as follows:

	Three Months Ended
	March 31,
	2016		2015

United States	$	13,416	$	18,020
France		(6,801)		7,880
Ireland		(5,850)		(3,780)
Total income before income taxes	$	765	$	22,120

The items accounting for the difference between the income tax provision computed at the French statutory rate and the Company's effective tax rate are as follows:

	Three Months Ended
	March 31,
	2016			2015

Statutory tax rate		33.3	%		33.3	%
International tax rates differential		190.8	%		4.9	%
Valuation allowance on net operating losses		317.4	%		(4.5)	%
Nondeductible contingent consideration		362.2	%		9.7	%
Nondeductible stock-based compensation		28.5	%		1.3	%
Deferred charge from IP transfer		64.6	%		1.2	%
State and local income taxes		15.8	%		0.5	%
Other		(79.2)	%		0.9	%
Effective income tax rate		933.5	%		47.3	%

Income tax provision - at Statutory tax rate	$	255		$	7,366
International tax rates differential		1,460			1,093
Valuation allowance on net operating losses		2,428			(1,006)
Nondeductible contingent consideration		2,771			2,146
Nondeductible stock-based compensation		218			285
Deferred charge from IP transfer		494			264
State and local income taxes		121			119
Other		(606)			206
Income tax provision - at Effective income tax rate	$	7,141		$	10,473

The effective tax rate for the first quarter 2016 and 2015 was 933.5% and 47.3%, respectively. The higher income tax rate in 2016 is primarily the result of recording valuation allowances against the tax benefits from book losses in France and Ireland. An increase in the amount of nondeductible contingent consideration and the effect of lower income levels in low-tax jurisdictions also contributed to the increased income tax rate.

Other Assets and Liabilities

3 Months Ended

Mar. 31, 2016

Other Liabilities Disclosure [Abstract]

Other Liabilities Disclosure [Text Block]

NOTE 9 : Other Assets and Liabilities

Various other assets and liabilities are summarized as follows:

	March 31,		December 31,
	2016		2015

Prepaid expenses and other current assets
Valued-added tax recoverable	$	1,182	$	1,099
Prepaid expenses		6,011		2,846
Advance to suppliers and other current assets		2,782		518
Income tax receivable		-		3,526
Total	$	9,975	$	7,989

	March 31,		December 31,
	2016		2015

Accrued expenses
Accrued compensation	$	1,898	$	1,888
Accrued social charges		1,285		1,710
Other		163		-
Total	$	3,346	$	3,598

	March 31,		December 31,
	2016		2015

Other current liabilities
Valued-added tax payable	$	134	$	-
Other		477		133
Total	$	611	$	133

	March 31,		December 31,
	2016		2015

Other non-current liabilities
Provision for retirement indemnity		2,297		2,170
Other		198		40
Total	$	2,495	$	2,210

Net Income (Loss) Per Share

3 Months Ended

Mar. 31, 2016

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

NOTE 10 : Net Income (Loss) Per Share

Basic net income (loss) per share is calculated using the weighted average number of shares outstanding during each period. The diluted net income (loss) per share calculation includes the impact of dilutive equity compensation awards and contingent consideration warrants.

A reconciliation of basic and diluted net income (loss) per share, together with the related shares outstanding in thousands is as follows:

	Three Months Ended
	March 31,
	2016		2015

Net income (loss)	$	(6,376)	$	11,647

Weighted average shares:
Basic shares		41,241		40,207
Effect of dilutive securities—options and warrants outstanding		-		2,672
Diluted shares		41,241		42,879

Net income (loss) per share - Basic	$	(0.15)	$	0.29
Net income (loss) per share - Diluted	$	(0.15)	$	0.27

Potential common shares of 6,597 and 72 were excluded from the calculation of weighted average shares for the three months ended March 31, 2016 and 2015, because their effect was considered to be anti-dilutive. For the quarter ended March 31, 2016, the effects of dilutive securities were entirely excluded from the calculation of net income (loss) per share as a net loss was reported in this period.

Comprehensive Income (Loss)

3 Months Ended

Mar. 31, 2016

Stockholders' Equity Note [Abstract]

Comprehensive Income (Loss) Note [Text Block]

NOTE 11 : Comprehensive Income (Loss)

The following table shows the components of accumulated other comprehensive income (loss) for the three months ended March 31, 2016 and 2015 net of tax effects:

	Foreign Currency
	Translation Adjustment Income		Unrealized Gain (Loss) on Marketable
	(Loss), Net		Securities, Net		Total

Balance - December 31, 2015	$	(22,312)	$	(345)	$	(22,657)
Other comprehensive income		4,817		918		5,735
Balance - March 31, 2016	$	(17,495)	$	573	$	(16,922)

Balance - December 31, 2014	$	(7,225)	$	(198)	$	(7,423)
Other comprehensive income (loss)		(16,649)		356		(16,293)
Balance - March 31, 2015	$	(23,874)	$	158	$	(23,716)

The effect on the Company’s consolidated financial statements of amounts reclassified out of Accumulated other comprehensive income was immaterial for all years presented.

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

Shareholders' Equity

3 Months Ended

Mar. 31, 2016

Stockholders' Equity Note [Abstract]

Stockholders Equity Note Disclosure [Text Block]

NOTE 12 : Shareholders’ Equity

The following table presents a reconciliation of the Company’s beginning and ending balances in shareholders’ equity for the three months ended March 31,:

	2016		2015

Shareholders' Equity - January 1	$	67,865	$	24,895
Net income (loss)		(6,376)		11,647
Other comprehensive income		5,735		(16,293)
Exercise of stock options or warrants		-		246
Stock-based compensation expense		2,475		1,751
Shareholders' Equity - March 31	$	69,699	$	22,246

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Company Operations by Product, Customer and Geographic Area

3 Months Ended

Mar. 31, 2016

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

NOTE 13 : Company Operations by Product, Customer and Geographic Area

The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer based technology. The Company's Chief Operating Decision Maker is the CEO. The CEO and the Board review profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the majority of our products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.

The following table presents a summary of total revenues by these products:

	Three Months Ended
	March 31,
	2016		2015

Bloxiverz	$	24,747	$	28,642
Vazculep		9,406		3,524
Other		1,200		560
Total product sales and services		35,353		32,726
License and research revenue		863		-
Total revenues	$	36,216	$	32,726

The following table presents a summary of total revenues by significant wholesaler customer:

	Three Months Ended
	March 31,
	2016		2015

Customer A	$	13,026	$	6,867
Customer B		10,677		13,771
Customer C		7,398		9,749
Other		4,252		2,339
Total product sales and services		35,353		32,726
License and research revenue		863		-
Total revenues	$	36,216	$	32,726

The following table summarizes revenues and non-monetary long-lived assets by geographic region. Non-monetary long-lived assets primarily consist of property and equipment, goodwill and intangible assets:

	2016		2015
Revenues, for the three months ended March 31,
United States	$	35,478	$	32,711
France		-		-
Ireland		738		15
Total	$	36,216	$	32,726

Long-lived assets, as of March 31, 2016 and December 31, 2015
United States	$	57,459	$	34,515
France		2,367		2,317
Ireland		256		258
Total	$	60,082	$	37,090

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

Related Party Transactions

3 Months Ended

Mar. 31, 2016

NOTE 14 : Related Party Transactions

In March 2012, the Company acquired all of the membership interests of Éclat from Breaking Stick Holdings, L.L.C. (“Breaking Stick”, formerly Éclat Holdings), an affiliate of Deerfield Capital L.P (“Deerfield”), a significant shareholder of the Company. As of March 31, 2016, the remaining consideration obligations for this transaction consisted of two warrants to purchase a total of 3,300 shares of Flamel and commitments to make earnout payments to Breaking Stick of 20% of any gross profit generated by certain Éclat products (the “Products”). Breaking Stick is majority owned by Deerfield, with a minority interest owned by Mr. Michael Anderson, the Company’s CEO, and certain other current and former employees. The original consideration for the acquisition of Éclat also included a $12 million senior note payable to the majority owners of Breaking Stick, which was fully repaid in March 2014 using the net proceeds from the Company’s public offering of ADS’s.

As part of a February 2013 debt financing transaction conducted with Deerfield Management, Éclat entered into a Royalty Agreement with Horizon Santé FLML, Sarl and Deerfield Private Design Fund II, L.P., both affiliates of the Deerfield Entities (together, “Deerfield PDF/Horizon”). The Royalty Agreement provides for Éclat to pay Deerfield PDF/Horizon 1.75% of the net sales of the Products sold by the Company and any of its affiliates until December 31, 2024, with royalty payments accruing daily and paid in arrears for each calendar quarter during the term of the Royalty Agreement. The Company has also entered into a Security Agreement dated February 4, 2013 with Deerfield PDF/Horizon, whereby Deerfield PDF/Horizon was granted a security interest in the intellectual property and regulatory rights related to the Products to secure the obligations of Éclat and Flamel US, including the full and prompt payment of royalties to Deerfield PDF/Horizon under the Royalty Agreement. This original Deerfield debt financing transaction also included a $15 million facility agreement which was repaid in full in March 2014 using the net proceeds from the Company’s public offering of ADS’s.

As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund (“Broadfin”), the Company entered into a Royalty Agreement with Broadfin, a significant shareholder of the Company, dated as of December 3, 2013 (the “Broadfin Royalty Agreement”). Pursuant to the Broadfin Royalty Agreement, the Company is required to pay a royalty of 0.834% on the net sales of certain products sold by the Company and any of its affiliates until December 31, 2024. This original Broadfin debt financing transaction also included a $5 million facility agreement which was repaid in full in March 2014 using the net proceeds from the Company’s public offering of ADS’s.

In February 2016, the Company acquired all of the membership interests of FSC Holdings, LLC (“FSC”) from Deerfield CSF, LLC, a Deerfield Management company (“Deerfield”), a significant shareholder of the Company. The consideration obligations for this transaction consisted of payments $1,050 annually for five years with a final payment in January 2021 of $15,000, and commitments to pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Contingent Liabilities and Commitments

3 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments And Contingencies Disclosure [Text Block]

NOTE 15 : Contingent Liabilities and Commitments

Litigation

The Company is subject to potential liabilities generally incidental to its business arising out of present and future lawsuits and claims related to product liability, personal injury, contract, commercial, intellectual property, tax, employment, compliance and other matters that arise in the ordinary course of business. The Company accrues for potential liabilities when it is probable that future costs (including legal fees and expenses) will be incurred and such costs can be reasonably estimated. At March 31, 2016 and December 31, 2015, there were no contingent liabilities with respect to any threat of litigation, arbitration or administrative or other proceeding that are reasonably likely to have a material adverse effect on the Company’s consolidated financial position, results of operations, cash flows or liquidity.

Material Commitments

Other than commitments to Recipharm and for operating leases as disclosed in Note 12 - Contingent Liabilities and Commitments to the Company's consolidated financial statements included in Part II, Item 8 of the Company’s 2015 Annual Report, there were no other material commitments outside of the normal course of business. Material commitments in the normal course of business include long-term debt, and post-retirement benefit plan obligations which are disclosed in Note 7 - Long-Term Debt and Note 10 – Post-Retirement Benefit Plans, respectively, to the Company's consolidated financial statements included in Part II, Item 8 of the Company’s 2015 Annual Report and long-term contingent consideration payable as disclosed in Note 7 – Long-term Contingent Consideration Payable, to the Company's consolidated financial statements included in Part I, Item 1 of this report.

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Nature Of Business Policy [Policy Text Block]

(i)

(ii)

a branded pediatric specialty pharmaceutical business, acquired through the acquisition of FSC Laboratories and FSC Pediatrics (“FSC”) on February 5, 2016; and

(iii)

Flamel is headquartered in Lyon, France and has operations in St. Louis, Missouri and Charlotte, NC, USA, and Dublin, Ireland.

Basis of Accounting, Policy [Policy Text Block]

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Reclassification, Policy [Policy Text Block]

Reclassifications. The accompanying consolidated financial statements for prior years contain certain reclassifications to conform to the presentation used in 2016.

Revenue Recognition, Policy [Policy Text Block]

Revenue. Revenue includes sales of pharmaceutical products, upfront licensing fees, milestone payments for R&D achievements, and compensation for the execution of R&D activities.

Product Sales and Services

License and Research Revenue

The Company uses a Multiple Attribution Model, referred to as the milestone-based method:

⋅

Revenue associated with signed feasibility study agreements is recognized over the term of the agreement as services are performed.

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

Marketable Securities (Tables)

3 Months Ended

Mar. 31, 2016

Investments, Debt and Equity Securities [Abstract]

Available-for-sale Securities [Table Text Block]

The value at cost, gross unrealized holding gains or losses, and fair value of the Company’s available-for-sale marketable securities are summarized below as of:

	March 31,		December 31,
	2016		2015
Value at cost	$	122,823	$	81,395
Gross unrealized holding gains		614		15
Gross unrealized holding losses		(1,353)		(1,672)
Fair value	$	122,084	$	79,738

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Inventories (Tables)

3 Months Ended

Mar. 31, 2016

Inventory Disclosure [Abstract]

Schedule of Inventory, Current [Table Text Block]

The principal categories of inventories at December 31, 2015 and 2014 are as follows:

	March 31,		December 31,
	2016		2015
Finished Goods	$	5,046	$	2,545
Raw Materials		266		1,610
Total	$	5,312	$	4,155

Acquisitions (Tables)

3 Months Ended

Mar. 31, 2016

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

Assigned Fair Value:
Inventories	$	2,360
Prepaid expenses and other current assets		1,711
Goodwill		5,564
Intangible assets:
Acquired product marketing rights		16,200
Acquired developed technology		4,400
Other assets		278
Accounts payable and other current liabilities		(3,868)
Deferred tax liabilities		(3,950)
Total	$	22,695

Goodwill and Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets [Table Text Block]

The Company's amortizable and unamortizable intangible assets at March 31, 2016 and December 31, 2015 are as follows:

	March 31, 2016						December 31, 2015
	Gross Value		Accumulated Amortization		Net Carrying Amount		Gross Value		Accumulated Amortization		Net Carrying Amount
Amortizable intangible assets:
Acquired IPR&D - Bloxiverz	$	35,248	$	(26,435)	$	8,813	$	35,248	$	(23,498)	$	11,750
Acquired IPR&D - Vazculep		12,061		(8,190)		3,871		12,061		(7,986)		4,075
Acquired product marketing rights		16,200		(300)		15,900		-		-		-
Acquired developed technology		4,400		(73)		4,327		-		-		-
Total amortizable intangible assets	$	67,909	$	(34,998)	$	32,911	$	47,309	$	(31,484)	$	15,825

Unamortizable intangible assets:
Goodwill		24,599		(544)		24,055		19,035		(544)		18,491
Total unamortizable intangible assets	$	24,599	$	(544)	$	24,055	$	19,035	$	(544)	$	18,491

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Estimated amortization of intangible assets for the next five years is as follows:

Years ending December 31,	Estimated Amortization Expense
2016	$	14,616
2017		3,056
2018		3,056
2019		3,056
2020		3,056
Total	$	26,840

Schedule of Goodwill [Table Text Block]

The change in net goodwill during the three months ended March 31, 2016 is as follows:

Balance - December 31, 2015	$	18,491
Impact of FSC Acquisition		5,564
Balance - March 31, 2016	$	24,055

Long-Term Contingent Consideration Payable (Tables)

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]

Long-term contingent consideration payable and related activity are reported at fair value and consist of the following at March 31, 2016 and December 31, 2015:

			Activity During Quarter Ended March 31, 2016
							Changes in Fair Value of Contingent Consideration
	Balance,						Operating Expense;		Interest Expense;		Balance,
	December 31, 2015		Additions		Payments to Related Parties		Acquisition- Related		Financing- Related		March 31, 2016

Acquisition-related:
Warrants - Éclat Pharmaceuticals (a)	$	20,617	$	-	$	-	$	(3,535)	$	-	$	17,082
Earn-out payments - Éclat Pharmaceuticals (b)		90,468		-		(8,014)		11,451		-		93,905
Financing-related:
Royalty agreement - Deerfield (c)		7,862		-		(739)		-		1,038		8,161
Royalty agreement - Broadfin (d)		3,746		-		(353)		-		496		3,889
Royalty agreement - FSC (e)		-		7,695		-		-		327		8,022
Total contingent consideration	$	122,693	$	7,695	$	(9,106)	$	7,916	$	1,861	$	131,059
Less: Current portion		(28,614)										(28,403)
Total long-term contingent consideration payable	$	94,079									$	102,656

(a)

(b)

(c)

(d)

(e)

Schedule Of Fair Value Assumptions Of Warrant [Table Text Block]

The fair value of the warrants is estimated on a quarterly basis using a Black-Scholes option pricing model with the following assumptions as of March 31,:

	2016			2015
Weighted average exercise price per share	$	8.63		$	8.63
Expected term (years)		2.00			3.00
Expected volatility		70.50	%		61.80	%
Risk-free interest rate		0.73	%		0.89	%
Expected dividend yield		-			-

Income Taxes (Tables)

3 Months Ended

Mar. 31, 2016

Income Tax Disclosure [Abstract]

Schedule Of Components Of Income Before Income Tax [Table Text Block]

The components of income (loss) before income taxes are as follows:

	Three Months Ended
	March 31,
	2016		2015

United States	$	13,416	$	18,020
France		(6,801)		7,880
Ireland		(5,850)		(3,780)
Total income before income taxes	$	765	$	22,120

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

The items accounting for the difference between the income tax provision computed at the French statutory rate and the Company's effective tax rate are as follows:

	Three Months Ended
	March 31,
	2016			2015

Statutory tax rate		33.3	%		33.3	%
International tax rates differential		190.8	%		4.9	%
Valuation allowance on net operating losses		317.4	%		(4.5)	%
Nondeductible contingent consideration		362.2	%		9.7	%
Nondeductible stock-based compensation		28.5	%		1.3	%
Deferred charge from IP transfer		64.6	%		1.2	%
State and local income taxes		15.8	%		0.5	%
Other		(79.2)	%		0.9	%
Effective income tax rate		933.5	%		47.3	%

Income tax provision - at Statutory tax rate	$	255		$	7,366
International tax rates differential		1,460			1,093
Valuation allowance on net operating losses		2,428			(1,006)
Nondeductible contingent consideration		2,771			2,146
Nondeductible stock-based compensation		218			285
Deferred charge from IP transfer		494			264
State and local income taxes		121			119
Other		(606)			206
Income tax provision - at Effective income tax rate	$	7,141		$	10,473

Other Assets and Liabilities (Tables)

3 Months Ended

Mar. 31, 2016

Other Liabilities Disclosure [Abstract]

Schedule Of Prepaid Expenses and Other Current Assets [Table Text Block]

	March 31,		December 31,
	2016		2015

Prepaid expenses and other current assets
Valued-added tax recoverable	$	1,182	$	1,099
Prepaid expenses		6,011		2,846
Advance to suppliers and other current assets		2,782		518
Income tax receivable		-		3,526
Total	$	9,975	$	7,989

Schedule of Accrued Liabilities [Table Text Block]

	March 31,		December 31,
	2016		2015

Accrued expenses
Accrued compensation	$	1,898	$	1,888
Accrued social charges		1,285		1,710
Other		163		-
Total	$	3,346	$	3,598

Schedule Of Other Current Liabilities [Table Text Block]

	March 31,		December 31,
	2016		2015

Other current liabilities
Valued-added tax payable	$	134	$	-
Other		477		133
Total	$	611	$	133

Schedule Of Long Term Liabilities [Table Text Block]

	March 31,		December 31,
	2016		2015

Other non-current liabilities
Provision for retirement indemnity		2,297		2,170
Other		198		40
Total	$	2,495	$	2,210

Net Income (Loss) Per Share (Tables)

3 Months Ended

Mar. 31, 2016

Earnings Per Share [Abstract]

Schedule of Earnings Per Share Reconciliation [Table Text Block]

A reconciliation of basic and diluted net income (loss) per share, together with the related shares outstanding in thousands is as follows:

	Three Months Ended
	March 31,
	2016		2015

Net income (loss)	$	(6,376)	$	11,647

Weighted average shares:
Basic shares		41,241		40,207
Effect of dilutive securities—options and warrants outstanding		-		2,672
Diluted shares		41,241		42,879

Net income (loss) per share - Basic	$	(0.15)	$	0.29
Net income (loss) per share - Diluted	$	(0.15)	$	0.27

Comprehensive Income (Loss) (Tables)

3 Months Ended

Mar. 31, 2016

Stockholders' Equity Note [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

The following table shows the components of accumulated other comprehensive income (loss) for the three months ended March 31, 2016 and 2015 net of tax effects:

	Foreign Currency
	Translation Adjustment Income		Unrealized Gain (Loss) on Marketable
	(Loss), Net		Securities, Net		Total

Balance - December 31, 2015	$	(22,312)	$	(345)	$	(22,657)
Other comprehensive income		4,817		918		5,735
Balance - March 31, 2016	$	(17,495)	$	573	$	(16,922)

Balance - December 31, 2014	$	(7,225)	$	(198)	$	(7,423)
Other comprehensive income (loss)		(16,649)		356		(16,293)
Balance - March 31, 2015	$	(23,874)	$	158	$	(23,716)

Shareholders' Equity (Tables)

3 Months Ended

Mar. 31, 2016

Stockholders' Equity Note [Abstract]

Schedule of Stockholders Equity [Table Text Block]

The following table presents a reconciliation of the Company’s beginning and ending balances in shareholders’ equity for the three months ended March 31,:

	2016		2015

Shareholders' Equity - January 1	$	67,865	$	24,895
Net income (loss)		(6,376)		11,647
Other comprehensive income		5,735		(16,293)
Exercise of stock options or warrants		-		246
Stock-based compensation expense		2,475		1,751
Shareholders' Equity - March 31	$	69,699	$	22,246

Company Operations by Product, Customer and Geographic Area (Tables)

3 Months Ended

Mar. 31, 2016

Segment Reporting Information [Line Items]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following table presents a summary of total revenues by these products:

	Three Months Ended
	March 31,
	2016		2015

Bloxiverz	$	24,747	$	28,642
Vazculep		9,406		3,524
Other		1,200		560
Total product sales and services		35,353		32,726
License and research revenue		863		-
Total revenues	$	36,216	$	32,726

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]

	2016		2015
Revenues, for the three months ended March 31,
United States	$	35,478	$	32,711
France		-		-
Ireland		738		15
Total	$	36,216	$	32,726

Long-lived assets, as of March 31, 2016 and December 31, 2015
United States	$	57,459	$	34,515
France		2,367		2,317
Ireland		256		258
Total	$	60,082	$	37,090

Wholesale Customer [Member]

Segment Reporting Information [Line Items]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following table presents a summary of total revenues by significant wholesaler customer:

	Three Months Ended
	March 31,
	2016		2015

Customer A	$	13,026	$	6,867
Customer B		10,677		13,771
Customer C		7,398		9,749
Other		4,252		2,339
Total product sales and services		35,353		32,726
License and research revenue		863		-
Total revenues	$	36,216	$	32,726

Marketable Securities (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
Marketable Securities (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Marketable Securities [Line Items]
Value at cost	$ 122,823	$ 81,395
Gross unrealized holding gains	614	15
Gross unrealized holding losses	(1,353)	(1,672)
Fair value	$ 122,084	$ 79,738

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Inventory [Line Items]
Finished Goods	$ 5,046	$ 2,545
Raw Materials	266	1,610
Total	$ 5,312	$ 4,155

Acquisitions (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Business Combination, Separately Recognized Transactions [Line Items]
Inventories	$ 2,360
Prepaid expenses and other current assets	1,711
Goodwill	24,055	$ 18,491
Intangible assets:
Other assets	278
Accounts payable and other current liabilities	(3,868)
Deferred Tax Liabilities	(3,950)
Net identifiable assets acquired	22,695
Product marketing rights [Member]
Intangible assets:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	16,200
Developed Technology Rights [Member]
Intangible assets:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	$ 4,400

Acquisitions (Details Textual) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended
Acquisitions (Details Textual) - USD ($) $ in Thousands	Feb. 05, 2016	Feb. 29, 2016	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Business Combination, Separately Recognized Transactions [Line Items]
Payments to Acquire Businesses, Gross			$ 9,106
Business Combination Royalty Payable Description	the Company shall pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual			(1,393)
Business Acquisition, Pro Forma Revenue			36,694	$ 33,226
Business Acquisition, Pro Forma Net Income (Loss)			(7,390)	$ 8,480
Business Combination, Contingent Consideration, Liability			131,059		$ 122,693
Deerfield CSF LLC [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	$ 15,000
Payments to Acquire Businesses, Gross	1,050
Business Combination, Contingent Consideration, Liability	7,695
FSC Holdings, LLC [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Business Combination, Consideration Transferred, Total	$ 22,695
Payments to Acquire Businesses, Gross		$ 1,050
Business Combination Royalty Payable Description		commitments to pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual			876
Business Acquisition, Transaction Costs			$ 76

Goodwill and Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Amortizable intangible assets: Gross Value	$ 67,909	$ 47,309
Amortizable intangible assets: Accumulated Amortization	(34,998)	(31,484)
Amortizable intangible assets: Net Carrying Value	32,911	15,825
Unamortizable intangible assets: Goodwill, Gross	24,599	19,035
Unamortizable intangible assets:Accumulated Amortization	(544)	(544)
Unamortizable intangible assets: Net Carrying Value	24,055	18,491
Goodwill [Member]
Finite-Lived Intangible Assets [Line Items]
Unamortizable intangible assets: Goodwill, Gross	24,599	19,035
Unamortizable intangible assets:Accumulated Amortization	(544)	(544)
Unamortizable intangible assets: Net Carrying Value	24,055	18,491
In Process Research and Development [Member] \| Vazculep [Member]
Finite-Lived Intangible Assets [Line Items]
Amortizable intangible assets: Gross Value	12,061	12,061
Amortizable intangible assets: Accumulated Amortization	(8,190)	(7,986)
Amortizable intangible assets: Net Carrying Value	3,871	4,075
In Process Research and Development [Member] \| Bloxiverz [Member]
Finite-Lived Intangible Assets [Line Items]
Amortizable intangible assets: Gross Value	35,248	35,248
Amortizable intangible assets: Accumulated Amortization	(26,435)	(23,498)
Amortizable intangible assets: Net Carrying Value	8,813	11,750
Product marketing rights [Member]
Finite-Lived Intangible Assets [Line Items]
Amortizable intangible assets: Gross Value	16,200	0
Amortizable intangible assets: Accumulated Amortization	(300)	0
Amortizable intangible assets: Net Carrying Value	15,900	0
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Amortizable intangible assets: Gross Value	4,400	0
Amortizable intangible assets: Accumulated Amortization	(73)	0
Amortizable intangible assets: Net Carrying Value	$ 4,327	$ 0

Goodwill and Intangible Assets (Details 1) $ in Thousands	Mar. 31, 2016 USD ($)
Finite-Lived Intangible Assets [Line Items]
2016	$ 14,616
2017	3,056
2018	3,056
2019	3,056
2020	3,056
Total	$ 26,840

Goodwill and Intangible Assets (Details 2) $ in Thousands	3 Months Ended
Goodwill and Intangible Assets (Details 2) $ in Thousands	Mar. 31, 2016 USD ($)
Goodwill [Line Items]
Balance, Beginning	$ 18,491
Impact of FSC Acquisition	5,564
Balance, Ending	$ 24,055

Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)	$ 3,514	$ 3,143

Long-Term Contingent Consideration Payable (Details) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2016

Mar. 31, 2015

Dec. 31, 2015

Business Acquisition, Contingent Consideration [Line Items]

Additions

$ 7,695

Payments to Related Parties

(9,106)

Operating Expense; Acquisition-Related

7,916

$ 5,254

Interest Expense; Financing-Related

1,861

Total contingent consideration

131,059

$ 122,693

Less: Current portion

28,403

28,614

Total long-term contingent consideration payable

102,656

$ 94,079

Warrant [Member] | Acquisition-related Costs [Member]

Business Acquisition, Contingent Consideration [Line Items]

Business Combination,Beginning

^[1]

20,617

Additions

^[1]

Payments to Related Parties

^[1]

Operating Expense; Acquisition-Related

^[1]

(3,535)

Interest Expense; Financing-Related

^[1]

Business Combination,Ending

^[1]

17,082

Earn Out Payments [Member] | Acquisition-related Costs [Member]

Business Acquisition, Contingent Consideration [Line Items]

Business Combination,Beginning

^[2]

90,468

Additions

^[2]

Payments to Related Parties

^[2]

(8,014)

Operating Expense; Acquisition-Related

^[2]

11,451

Interest Expense; Financing-Related

^[2]

Business Combination,Ending

^[2]

93,905

Deerfield Royalty agreement [Member] | Financing Related Costs [Member]

Business Acquisition, Contingent Consideration [Line Items]

Business Combination,Beginning

^[3]

7,862

Additions

^[3]

Payments to Related Parties

^[3]

(739)

Operating Expense; Acquisition-Related

^[3]

Interest Expense; Financing-Related

^[3]

1,038

Business Combination,Ending

^[3]

8,161

Broadfin Royalty agreement [Member] | Financing Related Costs [Member]

Business Acquisition, Contingent Consideration [Line Items]

Business Combination,Beginning

^[4]

3,746

Additions

^[4]

Payments to Related Parties

^[4]

(353)

Operating Expense; Acquisition-Related

^[4]

Interest Expense; Financing-Related

^[4]

496

Business Combination,Ending

^[4]

3,889

FSC Royalty Agreement [Member] | Financing Related Costs [Member]

Business Acquisition, Contingent Consideration [Line Items]

Business Combination,Beginning

^[5]

Additions

^[5]

7,695

Payments to Related Parties

^[5]

Operating Expense; Acquisition-Related

^[5]

Interest Expense; Financing-Related

^[5]

327

Business Combination,Ending

^[5]

$ 8,022

[1]	As part of the consideration for the Company’s acquisition of Éclat Pharmaceuticals, LLC on March 13, 2012, the Company issued two warrants with a six-year term which allow for the purchase of a combined total of 3,300 ordinary shares of Flamel. One warrant is exercisable for 2,200 shares at an exercise price of $7.44 per share, and the other warrant is exercisable for 1,100 shares at an exercise price of $11.00 per share.
[2]	As part of the consideration for the Company’s acquisition of Éclat Pharmaceuticals, LLC in March 2012, the Company committed to provide quarterly earn-out payments equal to 20% of any gross profit generated by certain Éclat Pharmaceuticals products. These payments will continue in perpetuity, to the extent revenues of the related product also continue in perpetuity.
[3]	As part of a February 2013 debt financing transaction conducted with Deerfield Management, a related party and current shareholder, the Company received cash of $2,600 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 1.75% royalty on the net sales of certain Éclat Pharmaceuticals products until December 31, 2024.
[4]	As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of $2,200 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 0.834% royalty on the net sales of certain Éclat Pharmaceuticals products until December 31, 2024.
[5]	As part of the consideration for the Company’s acquisition of FSC Holdings, LLC in February 2016, the Company entered into a royalty agreement whereby the Company shall pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years.

Long-Term Contingent Consideration Payable (Details 1) - Warrant [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Schedule of Capitalization, Long-term Debt [Line Items]
Weighted average exercise price per share	$ 8.63	$ 8.63
Expected term (years)	2 years	3 years
Expected volatility	70.50%	61.80%
Risk-free interest rate	0.73%	0.89%
Expected dividend yield	0.00%	0.00%

Long-Term Contingent Consideration Payable (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	1 Months Ended			12 Months Ended
	Feb. 29, 2016	Feb. 28, 2013	Mar. 31, 2012	Dec. 31, 2013
Line of Credit Facility [Line Items]
Cash Consideration Received On Royalty Agreement		$ 2,600		$ 2,200
Percentage Of Royalty Payable On Net Sales		1.75%		0.834%
Eclat Pharmaceuticals [Member]
Line of Credit Facility [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			3,300
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1,100
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 11.00
Percentage of Earn Out Payments			20.00%
FSC Holdings, LLC [Member]
Line of Credit Facility [Line Items]
Percentage Of Royalty Payable On Net Sales	15.00%
Royalty Amount	$ 12,500
Exercise Price 1 [Member] \| Eclat Pharmaceuticals [Member]
Line of Credit Facility [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			2,200
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 7.44

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015
Income Taxes [Line Items]
Income (loss) before income taxes	$ 765	$ 22,120
France [Member]
Income Taxes [Line Items]
Income (loss) before income taxes	(6,801)	7,880
United States [Member]
Income Taxes [Line Items]
Income (loss) before income taxes	13,416	18,020
Ireland [Member]
Income Taxes [Line Items]
Income (loss) before income taxes	$ (5,850)	$ (3,780)

Income Taxes (Details 1) - USD ($) $ in Thousands	3 Months Ended
Income Taxes (Details 1) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015
Income Taxes [Line Items]
Statutory tax rate	33.30%	33.30%
International tax rates differential	190.80%	4.90%
Valuation allowance on net operating losses	317.40%	(4.50%)
Nondeductible contingent consideration	362.20%	9.70%
Nondeductible stock-based compensation	28.50%	1.30%
Deferred charge from IP transfer	64.60%	1.20%
State and local income taxes	15.80%	0.50%
Other	(79.20%)	0.90%
Effective income tax rate	933.50%	47.30%
Income tax provision - at Statutory tax rate	$ 255	$ 7,366
International tax rates differential	1,460	1,093
Valuation allowance on net operating losses	2,428	(1,006)
Nondeductible contingent consideration	2,771	2,146
Nondeductible stock-based compensation	218	285
Deferred charge from IP transfer	494	264
State and local income taxes	121	119
Other	(606)	206
Income tax provision - at Effective income tax rate	$ 7,141	$ 10,473

Income Taxes (Details Textual)	3 Months Ended
Income Taxes (Details Textual)	Mar. 31, 2016	Mar. 31, 2015
Income Taxes [Line Items]
Effective Income Tax Rate Reconciliation, Percent, Total	933.50%	47.30%

Other Assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Prepaid expenses and other current assets
Valued-added tax recoverable	$ 1,182	$ 1,099
Prepaid expenses	6,011	2,846
Advance to suppliers and other current assets	2,782	518
Income tax receivable	0	3,526
Total	$ 9,975	$ 7,989

Other Assets and Liabilities (Details 1) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Accrued Expenses [Line Items]
Accrued compensation	$ 1,898	$ 1,888
Accrued social charges	1,285	1,710
Other	163	0
Total	$ 3,346	$ 3,598

Other Assets and Liabilities (Details 2) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Other Current And Long Term Liabilities [Line Items]
Valued-added tax payable	$ 134	$ 0
Other	477	133
Total	$ 611	$ 133

Other Assets and Liabilities (Details 3) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Other Current And Long Term Liabilities [Line Items]
Provision for retirement indemnity	$ 2,297	$ 2,170
Other	198	40
Total	$ 2,495	$ 2,210

Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Earnings Per Share [Line Items]
Net income (loss)	$ (6,376)	$ 11,647
Weighted average shares:
Basic shares	41,241	40,207
Effect of dilutive securities—options and warrants outstanding	$ 0	$ 2,672
Diluted shares	41,241	42,879
Effect of dilutive securities:
Net income (loss) per share - Basic (in dollars per share)	$ (0.15)	$ 0.29
Net income (loss) per share - Diluted (in dollars per share)	$ (0.15)	$ 0.27

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Net Income (Loss) Per Share (Details Textual) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,597	72

Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Class of Stock [Line Items]
Foreign Currency Translation Adjustment Income (Loss), Net, Beginning Balance	$ (22,312)	$ (7,225)
Foreign Currency Translation Adjustment Income (Loss), Net, Balance, Other comprehensive income (loss)	4,817	(16,649)
Foreign Currency Translation Adjustment Income (Loss), Net, Ending Balance	(17,495)	(23,874)
Unrealized Gain (Loss) on Marketable Securities, Net, Beginning Balance	(345)	(198)
Unrealized Gain (Loss) on Marketable Securities, Net, Other comprehensive income (loss)	918	356
Unrealized Gain (Loss) on Marketable Securities, Net, Ending Balance	573	158
Beginning Balance	(22,657)	(7,423)
Other comprehensive income (loss)	5,735	(16,293)
Ending Balance	$ (16,922)	$ (23,716)

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References + Details

Shareholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended
Shareholders' Equity (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015
Class of Stock [Line Items]
Shareholders' Equity - January 1	$ 67,865	$ 24,895
Net income (loss)	(6,376)	11,647
Other comprehensive income	5,735	(16,293)
Exercise of stock options or warrants	0	246
Stock-based compensation expense	2,475	1,593
Shareholders' Equity - March 31	$ 69,699	$ 22,246

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Company Operations by Product, Customer and Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Segment Reporting Information [Line Items]
Total product sales and services	$ 35,353	$ 32,726
License and research revenue	863	0
Total revenues	36,216	32,726
Bloxiverz [Member]
Segment Reporting Information [Line Items]
Total product sales and services	24,747	28,642
Vazculep [Member]
Segment Reporting Information [Line Items]
Total product sales and services	9,406	3,524
Other Products [Member]
Segment Reporting Information [Line Items]
Total product sales and services	$ 1,200	$ 560

Company Operations by Product, Customer and Geographic Area (Details 1) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Segment Reporting Information [Line Items]
Total product sales and services	$ 36,216	$ 32,726
License and research revenue	863	0
Total revenues	35,353	32,726
wholesaler Customer [Member]
Segment Reporting Information [Line Items]
Total product sales and services	35,353	32,726
License and research revenue	863	0
Total revenues	36,216	32,726
Customer A [Member] \| wholesaler Customer [Member]
Segment Reporting Information [Line Items]
Total product sales and services	13,026	6,867
Customer B [Member] \| wholesaler Customer [Member]
Segment Reporting Information [Line Items]
Total product sales and services	10,677	13,771
Customer C [Member] \| wholesaler Customer [Member]
Segment Reporting Information [Line Items]
Total product sales and services	7,398	9,749
Other Customers [Member] \| wholesaler Customer [Member]
Segment Reporting Information [Line Items]
Total product sales and services	$ 4,252	$ 2,339

Company Operations by Product, Customer and Geographic Area (Details 2) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Revenues, for the years ended December 31,
Revenue, Net, Total	$ 36,216	$ 32,726
Long-lived assets, as of December 31,
Long-Lived Assets	60,082		$ 37,090
UNITED STATES
Revenues, for the years ended December 31,
Revenue, Net, Total	35,478	32,711
Long-lived assets, as of December 31,
Long-Lived Assets	57,459		34,515
FRANCE
Revenues, for the years ended December 31,
Revenue, Net, Total	0	0
Long-lived assets, as of December 31,
Long-Lived Assets	2,367		2,317
IRELAND
Revenues, for the years ended December 31,
Revenue, Net, Total	738	$ 15
Long-lived assets, as of December 31,
Long-Lived Assets	$ 256		$ 258

Related Party Transactions (Details Textual) - USD ($) shares in Thousands, $ in Thousands		1 Months Ended				3 Months Ended	12 Months Ended
	Feb. 05, 2016	Jan. 31, 2021	Feb. 29, 2016	Mar. 31, 2014	Feb. 28, 2013	Mar. 31, 2016	Dec. 31, 2013
Payments to Acquire Businesses, Gross						$ 9,106
Business Combination Royalty Payable Description	the Company shall pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years
Deerfield Debt Financing [Member]
Repayments of Long-term Lines of Credit				$ 15,000
Broadfin Debt Financing [Member]
Repayments of Long-term Lines of Credit				5,000
Senior Notes [Member]
Repayments of Related Party Debt				$ 12,000
Royalty Arrangement [Member]
Long Term Debt Repayment Percentage					1.75%		0.834%
Debt Repayment Term					Dec. 31, 2024		Dec. 31, 2024
Eclat Pharmaceuticals [Member]
Warrants Issued During Period Warrants New Issues						3,300
Percentage Of Earn Out Payment						20.00%
FSC Holdings, LLC [Member]
Payments to Acquire Businesses, Gross			$ 1,050
Business Combination Royalty Payable Description			commitments to pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years
FSC Holdings, LLC [Member] \| Scenario, Forecast [Member]
Final Payments to Acquire Business Gross		$ 15,000